What Cefotan Treats: Main Uses and Benefits

---

The core therapeutic purpose of Cefotan (Cefotetan) is applied in clinical settings for the management of serious systemic bacterial infections and is considered relevant for prophylactic management in high-risk surgical scenarios. The medication is indicated for a wide range of infections, which supports its role in managing complicated patient cases.

Cefotan is generally used to address symptom clusters associated with established, acute infections, encompassing several therapeutic domains such as lower respiratory tract infections (e.g., bacterial pneumonia), urinary tract infections (UTI), intra-abdominal infections (e.g., peritonitis), and gynecologic infections (like Pelvic Inflammatory Disease).

Applied in contexts marked by heightened systemic burden, the treatment helps address symptoms related to systemic imbalance, such as high fever and profound physical discomfort. This approach assists with maintaining functional stability, contributing to improved comfort during symptomatic periods.

---

Quick Fact: Primary Uses
Symptom Management	Helps address fever and profound physical discomfort associated with acute infection.
Key Conditions	Used for managing intra-abdominal, gynecologic, and lower respiratory tract infections.
Preventative Role	Applied for the prevention of postoperative infections in high-risk surgical settings.

---

Beyond active treatment, Cefotan is commonly used to help with the prevention of postoperative infections in high-risk surgical scenarios. This preventative application is relevant when supportive symptom management is appropriate in situations where patients experience increased physiological stress following procedures like cesarean section or hysterectomy. This measure may assist with reducing the risk of complications and supports general well-being during symptomatic phases.

Regulatory References

1. NIH DailyMed Overview of Cefotetan

Eligibility Map: Who Can and Cannot Use Cefotan — Official Regulatory Information

---

Eligibility Scope

Classification	Population Group	Details (Regulatory Status)
Contraindicated	Hypersensitivity	Patients with known allergy to Cefotetan or other cephalosporin class antibiotics.
Contraindicated	Hemolytic Anemia History	Patients with a history of cephalosporin-associated immune hemolytic anemia.
Allowed (Adults)	Adult Patients	Standard-labeled population for treatment and surgical prophylaxis.
Not Established	Pediatric Patients	Safety and effectiveness have not been established in this population by the FDA.

---

Eligibility-Related Restrictions

• Impaired Renal Function: Use is permitted only under conditional circumstances that require a modified dosing schedule due to the drug's primary elimination via the kidneys.
• Pregnancy Status: Assigned FDA Pregnancy Category B. Use is regulated and permitted only if clearly needed, as adequate, controlled studies in pregnant women are lacking.
• Lactation Status: Cefotetan is excreted in human milk in very low concentrations, and caution should be exercised when administered to a nursing mother.
• Geriatric Patients: Use is allowed, but caution is advised due to the higher likelihood of decreased renal function in this age group, potentially requiring careful dose selection.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible population for Cefotetan by establishing absolute contraindications based on immune and allergic history. Beyond these explicit prohibitions, eligibility is strictly limited by age, as the drug is not established for pediatric use, and by renal function status, which requires a specific, regulated dosing schedule for conditional use.

Interactions with other medicines and products

Cefotetan, the active compound in Cefotan, has officially documented interaction patterns that are classified based on their effect and mechanism, as outlined in government regulatory labeling.

Documented Interaction Constraints

The most stringent restriction is the contraindication with Ethanol (Alcohol). Due to a metabolic inhibition, alcohol must be avoided during therapy and for 72 hours after the final dose to prevent a severe disulfiram-like reaction.

Another key constraint involves Aminoglycoside Antibiotics (such as gentamicin or amikacin); co-administration may potentiate nephrotoxicity, and the solutions must be administered separately and not physically mixed in the same intravenous line.

Pharmacodynamic and Exposure-Modifying Effects

The medication is associated with a fall in prothrombin activity, increasing the risk of bleeding when used with anticoagulants or in patients with pre-existing conditions like poor nutritional status or renal impairment.

Probenecid is documented to be an exposure-modifying substance that increases the plasma concentration of Cefotetan by interfering with its renal clearance. Additionally, Cefotetan may decrease the efficacy of oral contraceptives by altering intestinal flora. Live bacterial vaccines are also subject to potential pharmacodynamic antagonism.

Interference with Laboratory Tests

Cefotetan is officially noted to interfere with certain laboratory tests, including causing false positive results for urine glucose using non-specific reduction methods, and potentially interfering with the measurement of serum and urine creatinine levels.

Cefotetan's mechanism is defined by its highly targeted action against essential microbial processes, resulting in a definitive bacterial cellular outcome. The drug functions primarily through two interconnected domains: disrupting bacterial structure and overcoming microbial defenses.

Irreversible Inhibition of Cell Wall Assembly

Cefotetan acts as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes vital for cross-linking the structural components of the peptidoglycan cell wall. This molecular action immediately stops the cell wall from being properly constructed, causing the bacteria to lose their crucial structural integrity. This defect triggers the bacteria's own autolytic enzymes, which ultimately cause the cell to rupture rapidly (osmotic lysis), resulting in a definitive bactericidal effect.

Structural Stability Against Microbial Defenses

The structure of Cefotetan provides significant stability against hydrolysis by many common beta-lactamase enzymes produced by bacteria. While these enzymes typically inactivate most beta-lactam antibiotics, Cefotetan's unique molecular configuration allows it to evade hydrolysis. This structural stability helps the active drug molecule to reach and irreversibly bind its PBP targets, which supports the bactericidal cascade.

How to Use Cefotan: Official Administration Guidelines

Cefotan (cefotetan disodium) is supplied as an injectable powder or premixed solution, and its use is strictly confined to parenteral administration within a clinical setting. The drug is primarily delivered into a vein (intravenous or IV) or, in some cases, a large muscle (intramuscular or IM).

Standard Labeled Dosing Regimens

The usage schedule is defined by the indication and patient-specific factors. For established infections, the usual adult dosage ranges from 1 gram (g) to 2 g administered at regular intervals. Dosing is typically set at every 12 hours (q12h), although a once-daily (q24h) regimen is used for certain less-severe infections, such as those involving the urinary tract. For severe or life-threatening systemic infections, the dosage may be increased up to a maximum of 6 g daily.

For surgical prophylaxis, a single dose of 1 g to 2 g IV is administered 30 to 60 minutes prior to the surgical incision. The prophylactic dose may be repeated after surgery for no more than 24 hours.

Administration and Dose Modification

When Cefotan is prepared from the powder, it must be reconstituted using a specified diluent, such as Sterile Water for Injection. Solutions intended for IV infusion are administered over a specific duration, typically 20 to 60 minutes. It is specified that solutions of cefotetan must not be admixed with solutions containing aminoglycosides; they must be administered separately.

Crucially, a reduced dosing schedule is required for patients with impaired renal function. The dose or the frequency of administration must be adjusted based on the measured Creatinine Clearance to prevent drug accumulation in the body.

Research Evidence / Overview of Studies for Cefotan (Cefotetan)

This overview summarizes the structure and reported observations from the scientific research that supports the approved uses of Cefotetan, focusing on the types of studies conducted and what remains uncertain, based on official regulatory and peer-reviewed sources.

---

Evidence for Treatment of Established Bacterial Infections

Research on Intra-abdominal and Gynecologic Infections

The research base for this use includes Randomized Controlled Trials (RCTs) and comparative studies involving adult patients with serious, complex infections in areas like the abdomen (peritonitis) and the female reproductive tract (pelvic infections). The research examined outcomes related to clinical resolution (the disappearance of infection signs) and patterns related to the documented eradication of susceptible bacteria from the infection site. Findings described patterns observed in the studies related to clinical resolution.

However, data evaluating the outcome against non-treatment conditions (placebo) is limited, as the trials typically compare Cefotetan to other established antibiotic regimens. The follow-up durations were limited, mainly focused on the short course of antibiotic treatment, meaning long-term outcomes are not fully established.

---

Evidence for Prevention of Postoperative Infections (Prophylaxis)

This section describes the evidence base that was used to explore Cefotetan's association with the risk of infection following high-risk surgical procedures. The research includes numerous Randomized Controlled Trials (RCTs) and systematic reviews focusing on adult patients undergoing procedures such as colorectal and gynecologic surgery. The key outcome monitored was the incidence of postoperative infectious complications, such as surgical site infections (SSIs).

Studies reported measurements of infection rates, and the findings described patterns of results similar to those observed with other established prophylactic treatments. This evidence provides insight into short-term changes during the critical period right after surgery.

---

Evidence in Special Populations and Research Gaps

Special Populations

Studies have examined how the body processes Cefotetan in groups such as older adults (those over 65) with normal kidney function and patients with reduced kidney function. Pharmacokinetic data indicated that the elimination half-life of Cefotetan is prolonged in patients with impaired renal function.

For pediatric patients, the evidence is limited. While Cefotetan was evaluated in this group, scientific bodies have noted that the sample sizes were modest, and data for this specific group remain insufficient when compared to the data available for adults.

Research Gaps and Uncertainties

One research limitation is that many core comparative trials used older antibiotic agents as the comparator. This means subsequent research is needed to evaluate Cefotetan’s activity against constantly evolving antibiotic resistance patterns. Existing studies provide limited insight into long-term outcomes or the durability of the outcome over extended periods.

Key Studies & References

1. Cefotetan versus cefoxitin as prophylaxis in hysterectomy

Common questions about Cefotan (FAQ)

Q: Is Cefotan considered a 'broad-spectrum' antibiotic in official descriptions?

Yes, official regulatory documents describe Cefotan as a broad-spectrum cephamycin antibacterial. This classification indicates the medication is designed to fight a wide array of susceptible bacteria. Its structure also provides resistance against certain enzymes bacteria use to fight off antibiotics (beta-lactamase).

---

Q: How does the drug work differently from penicillin antibiotics?

Cefotetan is structurally different from penicillin, belonging to the cephalosporin class. A key difference described in official documents is Cefotetan’s stability against beta-lactamase enzymes. This structural feature allows the drug to avoid inactivation by certain defense mechanisms that some bacteria use against other antibiotics.

---

Q: Are there any common supplements or vitamins that may interact with Cefotan?

Official information indicates Cefotetan is associated with a risk of bleeding due to its effect on prothrombin activity. This risk is noted to be higher in patients with pre-existing conditions, including poor nutritional status or vitamin K deficiency.

---

Q: What does the term 'hemolytic anemia' mean in the context of Cefotan use?

Hemolytic anemia is described as a rare, serious blood-related event that has been associated with Cefotetan in post-marketing reports. The condition involves the destruction of the body's red blood cells. Signs of this condition can include unusual weakness, pale skin, or yellowing of the eyes or skin (jaundice).

---

Q: Why is close monitoring of blood cell counts sometimes necessary when receiving Cefotan?

Close monitoring of blood counts may be necessary because official safety information notes Cefotetan is associated with rare but serious hematologic adverse events. These adverse events include the risk of hemolytic anemia (a serious red blood cell condition) and prolonged prothrombin time, a measurement associated with the blood's ability to clot.

---

Q: What are the considerations for using Cefotan in patients with known bleeding disorders?

Official documents note that Cefotetan is associated with a fall in prothrombin activity, which increases the general risk of bleeding. Caution is specifically advised, and the patient's bleeding risk is a factor that is highlighted for evaluation prior to administration.

---

Q: Does Cefotan treat viral infections like the cold or flu?

Regulatory documents clarify that Cefotetan, like other antibacterial drugs, is intended only to eliminate bacterial infections. It is not effective against viral infections and is not indicated for their treatment, such as the common cold or influenza (the flu).

---

Q: How long does it usually take to notice an improvement after starting Cefotan?

Official patient information indicates that it is common for patients to feel better early in the course of treatment. However, to ensure the infection is fully resolved and to minimize the risk of bacterial resistance, the regulatory information highlights the importance of completing the full course of therapy exactly as it was prescribed.

---

Q: What happens if treatment with Cefotan is stopped before the full course is completed?

Official labeling emphasizes that stopping the medication too soon may decrease the effectiveness of the immediate treatment. It also notes that not completing the full course of therapy may increase the likelihood that bacteria will develop drug resistance.

---

Q: Is the interaction with alcohol unique to Cefotan among antibiotics?

Official information attributes the severe disulfiram-like reaction with alcohol to the presence of the N-methylthiotetrazole (NMTT) side chain in the drug's structure. Cefotetan is not the only antibiotic associated with this reaction; the NMTT side chain is also found on some other cephalosporin-class antibiotics.

---

Q: Is there a risk of developing a secondary yeast or fungal infection from Cefotan?

The official label warns that prolonged use of Cefotetan may result in the overgrowth of nonsusceptible organisms. This risk of superinfection—such as a yeast or fungal infection—is essential for careful observation if a superinfection develops.

---

Q: Does a history of seizures or epilepsy affect eligibility for Cefotan?

Regulatory documents state that cephalosporin-class antibiotics, including Cefotetan, have been implicated in triggering seizures. This risk is considered particularly relevant in patients who have impaired renal function when the dosage is not reduced as required by the prescribing information.

Storage and Disposal Requirements for Cefotan (Cefotetan)

Storage conditions for Cefotan are mandatory and depend on the product's form. The unreconstituted powder must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and must be protected from light.

Stability and Storage Limits

Form	Storage Temperature	Maximum Potency Period
Reconstituted Solution	Room Temp (25 C)	24 hours
Reconstituted Solution	Refrigerated (5 C)	96 hours

Crucially, solutions that have been frozen and thawed must not be refrozen. Furthermore, the Cefotetan supplied in ADD-Vantage Vials is restricted from being refrigerated or frozen once reconstituted.

All expired or unused product must be discarded in accordance with all local, state, and federal regulations. The product must also be stored out of the sight and reach of children.